JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Teen Success Project

  NCT03015805

  Condition:   Substance Abuse
  Interventions:   Behavioral: Contingency Management;   Behavioral: Probation as Usual
  Sponsors:   Oregon Social Learning Center;   George Mason University
  Recruiting
• A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis

  NCT02912351

  Condition:   Osteoarthritis
  Intervention:   Other: Patient record review, Radiographs, and questionaires.
  Sponsor:   Medacta USA
  Recruiting
• Dextromethorphan Pediatric Acute Cough Study

  NCT02651116

  Condition:   Cough
  Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
  Sponsor:   Pfizer
  Recruiting
• A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup

  NCT02196818

  Conditions:   Osteoarthritis;   Arthritis;   Avascular Necrosis;   Fracture of the Femoral Neck or Head;   Congenital Hip Dysplasia
  Intervention:   Device: Mpact Acetabular Shell
  Sponsor:   Medacta International SA
  Recruiting
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

  NCT03656510

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: JNJ-53718678;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

  NCT03740919

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Drug: LY900014;   Drug: Insulin Lispro
  Sponsor:   Eli Lilly and Company
  Recruiting
• An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

  NCT03120520

  Condition:   Chronic Idiopathic Constipation
  Interventions:   Drug: Plecanatide;   Drug: Matching placebo
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

  NCT02980133

  Condition:   Asthma
  Interventions:   Drug: Fp MDPI;   Drug: FS MDPI;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Completed
• A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

  NCT00475605

  Condition:   Atopic Dermatitis
  Intervention:  
  Sponsor:   LEO Pharma
  Terminated
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients

  NCT03924674

  Conditions:   Intravenous Fluids;   Fluid and Electrolyte Imbalance;   ADH Inappropriate
  Intervention:   Other: Education, clinical decision support tools
  Sponsors:   Seattle Children's Hospital;   American Academy of Pediatrics
  Active, not recruiting
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

  NCT03019185

  Condition:   Alport Syndrome
  Interventions:   Drug: Placebo Oral Capsule;   Drug: Bardoxolone Methyl
  Sponsor:   Reata Pharmaceuticals, Inc.
  Active, not recruiting
• A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

  NCT04102189

  Conditions:   Overweight;   Obesity
  Interventions:   Drug: Semaglutide;   Drug: Placebo
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

  NCT02918279

  Conditions:   Metabolism and Nutrition Disorder;   Obesity
  Interventions:   Drug: Liraglutide;   Drug: Placebo
  Sponsor:   Novo Nordisk A/S
  Completed
• Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

  NCT03636906

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
  Sponsor:   GlaxoSmithKline
  Active, not recruiting
• A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

  NCT03878446

  Condition:   Short Stature Children Born Small for Gestational Age (SGA)
  Interventions:   Drug: somapacitan;   Drug: Norditropin®
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Low-Dose Atropine for Treatment of Myopia

  NCT03334253

  Condition:   Myopia
  Interventions:   Drug: Atropine;   Other: Placebo Eyedrops
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Recruiting
• Growth and Tolerance of Infants Fed Milk-Based Infant Formula

  NCT03967132

  Condition:   Gastro-Intestinal Tolerance
  Interventions:   Other: Control Infant Formula;   Other: Experimental Infant Formula;   Other: Reference Group
  Sponsor:   Abbott Nutrition
  Recruiting
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

  NCT02141074

  Conditions:   Congenital Bleeding Disorder;   Haemophilia B
  Intervention:   Drug: nonacog beta pegol
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

  NCT04218929

  Conditions:   Infants;   Newborn
  Interventions:   Other: Study Formula (SF);   Other: Comparator Formula (CF)
  Sponsors:   ByHeart;   Paidion Research, Inc.
  Recruiting
• Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

  NCT04074928

  Condition:   Influenza, Human
  Interventions:   Biological: QIVc;   Biological: Comparator QIV
  Sponsor:   Seqirus
  Active, not recruiting
• Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

  NCT03875729

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Biological: teplizumab;   Biological: Placebo
  Sponsor:   Provention Bio, Inc.
  Recruiting
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

  NCT03796676

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

  NCT03695237

  Condition:   Central Precocious Puberty (CPP)
  Intervention:   Drug: Leuprolide Acetate (LA)
  Sponsor:   AbbVie
  Recruiting
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

  NCT03653364

  Condition:   Influenza
  Intervention:   Drug: Baloxavir Marboxil
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder

  NCT03569475

  Condition:   Major Depressive Disorder
  Interventions:   Drug: Levomilnacipran ER;   Drug: Fluoxetine;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty

  NCT03897595

  Condition:   Hip Osteoarthritis
  Intervention:   Device: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
  Sponsor:   Medacta USA
  Recruiting
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

  NCT03537508

  Condition:   Meningococcal Infections
  Interventions:   Biological: MenACYW conjugate vaccine;   Biological: MenACYW-135 conjugate vaccine;   Biological: DTaP-IPV//Hib vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Pentavalent rotavirus vaccine;   Biological: Hepatitis B vaccine;   Biological: Measles, mumps, rubella (MMR) vaccine;   Biological: Varicella vaccine;   Biological: Hepatitis A vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

  NCT03429543

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

  NCT02968004

  Condition:   Pediatric Growth Hormone Deficiency
  Interventions:   Drug: MOD-4023;   Drug: Somatropin
  Sponsor:   OPKO Health, Inc.
  Active, not recruiting
• Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

  NCT03338920

  Condition:   Acute Migraine With or Without Aura
  Interventions:   Drug: sumatriptan nasal powder;   Drug: Placebo
  Sponsor:   Currax Pharmaceuticals
  Active, not recruiting
• Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

  NCT03325881

  Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
  Interventions:   Drug: SHP465;   Drug: Placebo
  Sponsor:   Shire
  Completed
• Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

  NCT02914184

  Conditions:   Infections, Rotavirus;   Rotavirus Vaccines
  Interventions:   Biological: HRV PCV-free liquid vaccine;   Biological: Rotarix
  Sponsor:   GlaxoSmithKline
  Completed
• A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

  NCT03257644

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Ruxolitinib phosphate cream
  Sponsor:   Incyte Corporation
  Recruiting
• Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

  NCT03239873

  Condition:   Varicella
  Interventions:   Biological: VARIVAX® PE34 Process;   Biological: VARIVAX® 2016 Commercial Process;   Biological: M-M-R II®
  Sponsor:   Merck Sharp & Dohme Corp.
  Completed
• This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

  NCT03207750

  Conditions:   Rotavirus Infection;   Rotavirus Vaccines
  Interventions:   Biological: Rotarix;   Biological: Pediarix;   Biological: Hiberix;   Biological: Prevenar 13
  Sponsor:   GlaxoSmithKline
  Completed
• Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

  NCT03126227

  Condition:   Peanut Allergy
  Interventions:   Biological: AR101;   Biological: Placebo
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Binocular Dig Rush Game Treatment for Amblyopia

  NCT02983552

  Condition:   Amblyopia
  Interventions:   Other: iPad®;   Other: Spectacle correction
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Recruiting
• A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

  NCT02963766

  Condition:   Type 2 Diabetes
  Interventions:   Drug: Dulaglutide;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

  NCT02953314

  Condition:   Cystic Fibrosis
  Interventions:   Drug: TEZ;   Drug: TEZ/IVA;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Completed
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Trial of Overminus Spectacle Therapy for Intermittent Exotropia

  NCT02807350

  Condition:   Intermittent Exotropia
  Interventions:   Device: Overminus treatment;   Device: Non-overminus treatment
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Active, not recruiting
• Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

  NCT02660827

  Condition:   Type 1 Diabetes
  Intervention:   Device: Insulin Pump
  Sponsor:   Medtronic Diabetes
  Active, not recruiting
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

  NCT02618434

  Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
  Interventions:   Drug: SPN-810;   Drug: Placebo
  Sponsor:   Supernus Pharmaceuticals, Inc.
  Completed
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

  NCT02137850

  Conditions:   Congenital Bleeding Disorder;   Haemophilia A
  Intervention:   Drug: turoctocog alfa pegol
  Sponsor:   Novo Nordisk A/S
  Enrolling by invitation
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

  NCT02369653

  Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
  Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

  NCT02096263

  Conditions:   Poliomyelitis;   Diphtheria;   Haemophilus Influenzae Type b;   Tetanus;   Acellular Pertussis;   Hepatitis B
  Interventions:   Biological: Infanrix hexa;   Biological: Pediarix;   Biological: ActHIB;   Biological: Pentacel;   Biological: Engerix-B;   Biological: Infanrix;   Biological: Hiberix;   Biological: Prevnar13;   Biological: Rotarix
  Sponsor:   GlaxoSmithKline
  Completed
• A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

  NCT01731600

  Conditions:   Congenital Bleeding Disorder;   Haemophilia A
  Intervention:   Drug: turoctocog alfa pegol
  Sponsor:   Novo Nordisk A/S
  Completed
• Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

  NCT01702428

  Conditions:   Rubella;   Measles;   Mumps
  Interventions:   Biological: Priorix;   Biological: M-M-R II;   Biological: Varivax;   Biological: Havrix;   Biological: Prevnar 13
  Sponsor:   GlaxoSmithKline
  Completed
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

  NCT01621802

  Condition:   Measles-Mumps-Rubella
  Interventions:   Biological: Priorix;   Biological: M-M-R II;   Biological: Kinrix;   Biological: ProQuad
  Sponsor:   GlaxoSmithKline
  Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

  NCT01460160

  Condition:   Leukemia, Pediatric
  Intervention:   Drug: Dasatinib
  Sponsors:   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL
  Active, not recruiting
• Study of Blood Samples From Newborns With Down Syndrome

  NCT00959283

  Condition:   Myeloid Proliferations Associated With Down Syndrome
  Interventions:   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

  NCT00861744

  Conditions:   Rubella;   Mumps;   Measles;   Measles-Mumps-Rubella Vaccine
  Interventions:   Biological: GSK Biological's investigational vaccine 209762;   Biological: M-M-R® II (Merck and Co);   Biological: Varivax®;   Biological: Havrix®;   Biological: Prevnar®
  Sponsor:   GlaxoSmithKline
  Completed
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  NCT00606346

  Conditions:   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
  Interventions:   Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
  Sponsor:   Janssen Biotech, Inc.
  Active, not recruiting
• Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

  NCT00499616

  Condition:   Neuroblastoma
  Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride;   Drug: Isotretinoin;   Procedure: Surgery;   Drug: Filgrastim
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

  NCT00369317

  Conditions:   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
  Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488

  Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

  NCT03377556

  Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

  NCT03091660

  Conditions:   Stage 0 Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Urothelial Carcinoma
  Interventions:   Biological: BCG Solution;   Biological: BCG Tokyo-172 Strain Solution;   Biological: BCG Tokyo-172 Strain Vaccine;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

  NCT02642042

  Conditions:   KRAS Gene Mutation;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867

  Conditions:   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Fibrosarcoma;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma AJCC v7;   Stage IIB Soft Tissue Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
  Interventions:   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338

  Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
  Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

  NCT01598298

  Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
  Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Completed
• Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

  NCT03605862

  Conditions:   Enterovirus;   Rhinovirus
  Interventions:   Drug: Nitazoxanide;   Drug: Placebo
  Sponsor:   Romark Laboratories L.C.
  Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• CLUSTER Trial for Outbreak Detection and Response

  NCT04053075

  Condition:   Cluster Detection
  Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
  Recruiting
• A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

  NCT04040192

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Crisaborole 2%;   Drug: Vehicle
  Sponsor:   Pfizer
  Recruiting
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

  NCT03749447

  Conditions:   Chronic Kidney Diseases;   Alport Syndrome
  Intervention:   Drug: Bardoxolone methyl
  Sponsor:   Reata Pharmaceuticals, Inc.
  Recruiting
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

  NCT03575871

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Completed
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

  NCT03358147

  Condition:   Asthma
  Interventions:   Drug: GP MDI 28.8 μg;   Drug: GP MDI 14.4 μg;   Drug: GP MDI 7.2 μg;   Drug: Placebo MDI;   Drug: Spiriva Respimat 2.5 μg
  Sponsor:   Pearl Therapeutics, Inc.
  Completed
• Mupirocin-Iodophor ICU Decolonization Swap Out Trial

  NCT03140423

  Condition:   Staphylococcus Aureus
  Interventions:   Drug: Arm 1. Routine Care (Mupirocin/CHG);   Drug: Arm 2. Iodophor/CHG Decolonization
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America;   University of California, Irvine;   University of Massachusetts, Amherst;   Rush University;   Centers for Disease Control and Prevention
  Active, not recruiting
• Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

  NCT04056299

  Condition:   Hen Egg Allergy
  Interventions:   Biological: AR201 Powder;   Biological: Placebo powder
  Sponsor:   Aimmune Therapeutics, Inc.
  Recruiting
• Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

  NCT03969212

  Condition:   Influenza
  Interventions:   Drug: Baloxavir Marboxil;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

  NCT03914625

  Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
  Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03698994

  Conditions:   Advanced Malignant Solid Neoplasm;   MAPK1 Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD

  NCT03633799

  Condition:   Women at Risk for Pregnancy
  Intervention:   Drug: VeraCept
  Sponsors:   Sebela Pharmaceuticals Inc.;   Synteract, Inc.
  Active, not recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• AR101 Real-World Open-Label Extension Study

  NCT03337542

  Condition:   Peanut Allergy
  Intervention:   Biological: AR101
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)

  NCT03245840

  Condition:   Eosinophilic Esophagitis (EoE)
  Intervention:   Drug: Budesonide oral suspension
  Sponsor:   Shire
  Recruiting
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
  Intervention:   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
  Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Selumetinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

  NCT03199053

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia;   T Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• PALISADE Follow-on Study (ARC004)

  NCT02993107

  Condition:   Peanut Allergy
  Intervention:   Biological: AR101
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

  NCT02986854

  Condition:   Infections, Meningococcal
  Intervention:   Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
  Sponsor:   GlaxoSmithKline
  Completed
• Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

  NCT02981628

  Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
  Interventions:   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049

  Conditions:   B Acute Lymphoblastic Leukemia;   Central Nervous System Leukemia;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia
  Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

  NCT02846545

  Condition:   Diabetes Mellitus, Type 1
  Interventions:   Biological: Golimumab;   Biological: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Active, not recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Condition:   Medulloblastoma
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Neuroblastoma Maintenance Therapy Trial

  NCT02679144

  Condition:   Neuroblastoma
  Intervention:   Drug: Difluoromethylornithine (DFMO)
  Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
  Recruiting
• Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

  NCT02635776

  Condition:   Peanut Allergy
  Interventions:   Biological: AR101 powder provided in capsules & sachets;   Biological: Placebo powder provided in capsules & sachets
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee

  NCT01754298

  Condition:   Juvenile Osteochondritis Dissecans
  Interventions:   Procedure: Retro-articular drilling;   Procedure: Trans-articular drilling
  Sponsors:   Boston Children’s Hospital;   Pediatric Orthopaedic Society of North America;   University of Pennsylvania;   Tennessee Orthopedic Alliance;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Washington University School of Medicine;   The Hospital for Sick Children;   Children's Hospital of Philadelphia;   Kaiser Permanente;   Rady Children's Hospital, San Diego;   St. Luke's Children's Hospital;   Medical College of Wisconsin;   Connecticut Children's Medical Center;   Hospital for Special Surgery, New York
  Active, not recruiting
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

  NCT02605837

  Condition:   Eosinophilic Esophagitis (EoE)
  Interventions:   Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
  Sponsor:   Shire
  Completed
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

  NCT02484443

  Conditions:   Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
  Interventions:   Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091

  Conditions:   Metastatic Osteosarcoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Stage IV Osteosarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7
  Interventions:   Biological: Denosumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

  NCT02452554

  Conditions:   Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

  NCT02339740

  Condition:   Acute Promyelocytic Leukemia With PML-RARA
  Interventions:   Drug: Arsenic Trioxide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tretinoin
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161

  Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma

  NCT02166463

  Conditions:   Ann Arbor Stage IIB Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Childhood Hodgkin Lymphoma;   Classic Hodgkin Lymphoma
  Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

  NCT02112916

  Conditions:   Adult T Acute Lymphoblastic Leukemia;   Ann Arbor Stage II Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage III Adult Lymphoblastic Lymphoma;   Ann Arbor Stage III Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage IV Adult Lymphoblastic Lymphoma;   Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma;   Childhood T Acute Lymphoblastic Leukemia
  Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

  NCT02101853

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

  NCT02054156

  Condition:   Cystic Fibrosis
  Interventions:   Drug: azithromycin;   Drug: placebo;   Drug: Tobramycin solution for inhalation
  Sponsors:   Bonnie Ramsey;   National Heart, Lung, and Blood Institute (NHLBI)
  Completed
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536

  Conditions:   Anaplastic Large Cell Lymphoma, ALK-Positive;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233

  Conditions:   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Hodgkin Lymphoma;   Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01780662

  Conditions:   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Refractory Childhood Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Gemcitabine Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666

  Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Childhood Central Nervous System Germinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Radiation: Intensity-Modulated Radiation Therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149

  Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
  Interventions:   Drug: Lenalidomide;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981

  Conditions:   Acute Myeloid Leukemia;   Leukemia Cutis;   Myeloid Neoplasm;   Myeloid Sarcoma
  Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

  NCT01307579

  Conditions:   Acute Myeloid Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia With Minimal Differentiation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Fungal Infection;   Myeloid Neoplasm;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
  Interventions:   Drug: Caspofungin Acetate;   Drug: Fluconazole;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906

  Conditions:   Non-Metastatic Extraskeletal Ewing Sarcoma;   Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

  NCT00137969

  Condition:   Lupus Erythematosus, Systemic
  Interventions:   Drug: Rituximab;   Drug: Placebo;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine
  Sponsor:   Genentech, Inc.
  Completed
• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

  NCT01217437

  Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified
  Interventions:   Biological: Bevacizumab;   Drug: Irinotecan Hydrochloride;   Drug: Temozolomide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930

  Conditions:   Acute Lymphoblastic Leukemia;   Adult B Lymphoblastic Lymphoma;   Ann Arbor Stage I B Lymphoblastic Lymphoma;   Ann Arbor Stage II B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Hypodiploid B Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive
  Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT01142427

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368

  Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Papillary Ependymoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460

  Conditions:   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
  Interventions:   Drug: Cisplatin;   Drug: Dexrazoxane;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009

  Conditions:   Adult Kidney Wilms Tumor;   Beckwith-Wiedemann Syndrome;   Childhood Kidney Wilms Tumor;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Hemihypertrophy;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage II Kidney Wilms Tumor;   Stage III Kidney Wilms Tumor;   Stage IV Kidney Wilms Tumor;   Stage V Kidney Wilms Tumor
  Interventions:   Biological: Dactinomycin;   Drug: Doxorubicin Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

  NCT00919269

  Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid-Type Fibromatosis;   Metastatic Childhood Soft Tissue Sarcoma;   Non-Metastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Rhabdomyosarcoma;   Stage I Adult Soft Tissue Sarcoma AJCC v7;   Stage II Adult Soft Tissue Sarcoma AJCC v7;   Stage III Adult Soft Tissue Sarcoma AJCC v7;   Stage IV Adult Soft Tissue Sarcoma AJCC v7;   Untreated Childhood Rhabdomyosarcoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

  NCT00899990

  Conditions:   Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  Intervention:   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Study of Kidney Tumors in Younger Patients

  NCT00898365

  Conditions:   Adult Cystic Nephroma;   Anaplastic Kidney Wilms Tumor;   Angiolipoma;   Cellular Congenital Mesoblastic Nephroma;   Classic Congenital Mesoblastic Nephroma;   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Cystic Partially Differentiated Kidney Nephroblastoma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Extrarenal Rhabdoid Tumor;   Kidney Medullary Carcinoma;   Kidney Neoplasm;   Kidney Oncocytoma;   Kidney Wilms Tumor;   Metanephric Adenofibroma;   Metanephric Adenoma;   Metanephric Stromal Tumor;   Metanephric Tumor;   Mixed Congenital Mesoblastic Nephroma;   Ossifying Renal Tumor of Infancy;   Papillary Renal Cell Carcinoma;   Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Rhabdoid Tumor of the Kidney;   Wilms Tumor
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Suspended
• Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

  NCT00897325

  Conditions:   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Non-Hodgkin Lymphoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

  NCT00392327

  Conditions:   Anaplastic Medulloblastoma;   Medulloblastoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340

  Conditions:   Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q;   Stage IV Wilms Tumor
  Interventions:   Drug: doxorubicin hydrochloride;   Drug: liposomal vincristine sulfate;   Procedure: conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: etoposide
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Radiation Therapy in Treating Young Patients With Gliomas

  NCT00238264

  Conditions:   Brain Tumor;   Central Nervous System Tumor
  Intervention:   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745

  Condition:   Childhood Malignant Neoplasm
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

  NCT00075725

  Condition:   Leukemia
  Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

  NCT00075582

  Conditions:   Adult Rhabdomyosarcoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma
  Interventions:   Procedure: conventional surgery;   Drug: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

  NCT00027846

  Conditions:   Brain Tumor;   Central Nervous System Tumor
  Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Drug: Mesna;   Procedure: therapeutic conventional surgery
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

  NCT00004228

  Condition:   Lymphoma
  Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Safety and Tolerability Study of Diazepam Buccal Soluble Film (DBSF) in Subjects With Epilepsy

  NCT03428360

  Condition:   Epilepsy
  Intervention:   Drug: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5, and 15 mg
  Sponsors:   Aquestive Therapeutics;   Inventiv Health;   Covance
  Recruiting
• Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

  NCT04214652

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-126 Gel;   Drug: IDP-126 Vehicle Gel
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

  NCT03460990

  Condition:   Cystic Fibrosis
  Interventions:   Drug: VX-659/TEZ/IVA;   Drug: TEZ/IVA;   Drug: IVA;   Drug: Placebo
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Completed
• Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03916081

  Condition:   Atopic Dermatitis
  Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle
  Sponsor:   Arcutis Biotherapeutics, Inc.
  Completed
• Molecular Genetics Studies of Cancer Patients and Their Relatives

  NCT04185935

  Condition:   Malignant Neoplasm
  Interventions:   Other: Biospecimen Collection;   Other: Questionnaire Administration
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

  NCT04128007

  Condition:   Plaque Psoriasis
  Intervention:   Drug: ARQ-154
  Sponsor:   Arcutis Biotherapeutics, Inc.
  Recruiting
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

  NCT04043806

  Condition:   Cystic Fibrosis
  Interventions:   Drug: ELX/TEZ/IVA;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Recruiting
• Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.

  NCT04036435

  Condition:   Psoriasis
  Intervention:   Drug: BMS-986165
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Long-Term PF-06651600 for the Treatment of Alopecia Areata

  NCT04006457

  Condition:   Alopecia Areata
  Intervention:   Drug: PF-06651600
  Sponsor:   Pfizer
  Recruiting
• Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

  NCT03989349

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Recruiting
• Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Intervention:   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Not yet recruiting
• Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

  NCT03987620

  Condition:   Candida Vulvovaginitis
  Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
  Sponsors:   Scynexis, Inc.;   PPD
  Recruiting
• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

  NCT03985943

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Recruiting
• Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

  NCT03959423

  Condition:   Type 1 Diabetes Mellitus
  Intervention:   Device: AHCL insulin pump system
  Sponsor:   Medtronic Diabetes
  Recruiting
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Etrasimod
  Sponsor:   Arena Pharmaceuticals
  Recruiting
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03945188

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Etrasimod;   Drug: Placebo
  Sponsor:   Arena Pharmaceuticals
  Recruiting
• A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

  NCT03927716

  Condition:   Molluscum Contagiosum
  Interventions:   Drug: SB206 12%;   Drug: Placebo
  Sponsors:   Novan, Inc.;   Synteract, Inc.
  Active, not recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Study in Subjects With Moderate Atopic Dermatitis

  NCT03859986

  Condition:   Atopic Dermatitis Eczema
  Interventions:   Drug: ALX-101 Gel Vehicle;   Drug: ALX-101 Gel 5%
  Sponsor:   Ralexar Therapeutics, Inc.
  Active, not recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

  NCT03847896

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Budesonide metered-dose inhaler 160 µg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg;   Combination Product: Placebo metered-dose inhaler
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03745651

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
  Sponsor:   Incyte Corporation
  Active, not recruiting
• PF-06651600 for the Treatment of Alopecia Areata

  NCT03732807

  Condition:   Alopecia Areata
  Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

  NCT03706079

  Condition:   Asthma
  Interventions:   Biological: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Enrolling by invitation
• Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

  NCT03633617

  Condition:   Eosinophilic Esophagitis
  Interventions:   Drug: Dupilumab;   Drug: Placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

  NCT03607422

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

  NCT03580369

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

  NCT03580356

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib;   Drug: Topical corticosteroids (TCS)
  Sponsor:   AbbVie
  Recruiting
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

  NCT03467958

  Condition:   Crohn Disease
  Intervention:   Drug: Ozanimod
  Sponsor:   Celgene
  Recruiting
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

  NCT03464097

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

  NCT03446001

  Condition:   Alzheimer Disease
  Interventions:   Drug: TRx0237 16 mg/day;   Drug: Placebo;   Drug: TRx0237 8 mg/day
  Sponsor:   TauRx Therapeutics Ltd
  Active, not recruiting
• Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

  NCT03440385

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

  NCT03347279

  Condition:   Asthma
  Interventions:   Biological: Experimental: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Active, not recruiting
• An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

  NCT03259633

  Condition:   NF type1 With Inoperable Plexiform Neurofibromas
  Intervention:   Drug: Selumetinib
  Sponsor:   AstraZeneca
  Available
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

  NCT03189875

  Condition:   Systemic Lupus Erythematosus
  Intervention:   Other: Standard of Care
  Sponsor:   AstraZeneca
  Active, not recruiting
• A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

  NCT03170388

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-126 Gel;   Drug: IDP-126 Component A;   Drug: IDP-126 Component B;   Drug: IDP-126 Component C;   Drug: IDP-126 Vehicle Gel
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

  NCT03150719

  Condition:   Cystic Fibrosis
  Interventions:   Drug: Tezacaftor/Ivacaftor;   Drug: Ivacaftor;   Drug: Placebo
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Completed
• Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo

  NCT03004924

  Condition:   Bacterial Conjunctivitis
  Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
  Sponsor:   Shire
  Completed
• Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

  NCT02932306

  Condition:   Acne
  Interventions:   Drug: IDP-121 Lotion;   Drug: IDP-121 Vehicle Lotion
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

  NCT02834793

  Condition:   Lennox-Gastaut Syndrome (LGS)
  Interventions:   Drug: Placebo;   Drug: Perampanel
  Sponsor:   Eisai Inc.
  Recruiting
• Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

  NCT02748018

  Condition:   Type 1 Diabetes
  Interventions:   Device: 670G Insulin Pump;   Device: Subject's Current Diabetes Therapy
  Sponsor:   Medtronic Diabetes
  Recruiting
• Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

  NCT02677701

  Condition:   Cystic Fibrosis
  Interventions:   Drug: azithromycin;   Drug: placebo (for azithromycin);   Drug: inhaled tobramycin
  Sponsors:   Seattle Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center
  Active, not recruiting
• Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

  NCT02566369

  Condition:   Acne Vulgaris
  Interventions:   Drug: CD5789 (trifarotene) 50μg/g cream;   Drug: Placebo cream
  Sponsor:   Galderma R&D
  Completed
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation

  NCT02565914

  Condition:   Cystic Fibrosis
  Interventions:   Drug: VX-661/ivacaftor;   Drug: ivacaftor
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Enrolling by invitation
• Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

  NCT02531126

  Condition:   Ulcerative Colitis
  Intervention:   Drug: RPC1063
  Sponsor:   Celgene
  Recruiting
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

  NCT02435992

  Condition:   Ulcerative Colitis
  Interventions:   Drug: RPC1063;   Drug: Placebo
  Sponsor:   Celgene
  Recruiting
• Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures

  NCT02408549

  Condition:   Epilepsy
  Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution
  Sponsor:   UCB BIOSCIENCES, Inc.
  Active, not recruiting
• A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

  NCT02408523

  Condition:   Epilepsy
  Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution;   Other: Placebo Tablet;   Other: Placebo Oral Solution
  Sponsors:   UCB BIOSCIENCES, Inc.;   Pharmaceutical Research Associates
  Completed
• Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

  NCT02269241

  Condition:   Contraception
  Intervention:   Drug: LF111 (drospirenone)
  Sponsors:   Laboratories Leon Farma, S.A.;   Chemo France
  Completed
• A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

  NCT02161185

  Condition:   Epilepsy
  Intervention:   Drug: USL261
  Sponsor:   UCB Biopharma S.P.R.L.
  Terminated
• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

  NCT02134028

  Condition:   Asthma
  Intervention:   Drug: dupilumab SAR231893 (REGN668)
  Sponsors:   Sanofi;   Regeneron Pharmaceuticals
  Completed
• Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

  NCT00513695

  Conditions:   Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Completed
• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

  NCT01767194

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Drug: Temozolomide;   Drug: Temsirolimus
  Sponsors:   National Cancer Institute (NCI);   United Therapeutics
  Completed